Three European nations are amending their policies in order to create better conditions for biosimilar uptake and the cost savings that biosimilars provide to health systems.
Three European nations are amending their policies in order to create better conditions for biosimilar uptake and the cost savings that biosimilars provide to health systems.
Finnish Medicines Agency Initiates Study on Biosimilars
The Finnish Medicines Agency (Fimea) has announced that it is beginning a study to investigate factors that promote or prevent the uptake of biosimilar therapies. The study, which will be jointly funded by the Finnish Social Insurance Institution Kela and the Ministry of Social Affairs and Health, will comprise interviews of physicians who treat rheumatic diseases, inflammatory bowel disease, psoriasis, and diabetes in both university hospitals and in central hospitals across Finland. Patients who receive biologic therapies will also take part in interviews.
Fimea expects to publish the study’s results in 2019, and says that the data will provide “…support of pharmaco-political decision-making and help in promoting the implementation of rational pharmacotherapy in Finland.”
Switzerland to Allow US-Licensed Comparator Biologics in Clinical Trials
The Swiss Agency for Therapeutic Products (Swissmedic) has updated its guidance concerning the use of comparator products used in clinical trials of biosimilars.
Previously, Swissmedic held that the only acceptable comparator products were those authorized in Switzerland or the European Union, though for supplementary studies (non-pivotal studies on pharmacodynamics, pharmacokinetics, and additional studies on efficacy and safety), comparator products from Japan were accepted. In its updated guidance, Swissmedic says that comparator products can now originate from the United States, and for supplementary studies, Canadian products will be allowed.
If the reference drug (the originator biologic approved in Switzerland) and the comparator products are not identical, their equivalence must be demonstrated.
Biosimilar developers will also be required to submit an Environmental Risk Assessment to Swissmedic.
France Seeks to Reach 80% Biosimilar Penetration by 2022
RAPS reports that France has committed to increasing biosimilar penetration to 80% by 2022 in its new health strategy for 2018 to 2022. According to the plan’s objective, when biosimilar products are available, 80% of patients should receive biosimilar options rather than reference biologics (a 10% increase on last year’s target numbers). The plan also encourages the non-medical switching of patients who are already receiving biologic therapy to treatment with available biosimilars.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
The Banking of Biosimilars: Insights From a Leading Health Economist
February 4th 2025Biosimilars have the potential to reduce health care costs and expand patient access, but economic and policy barriers affect adoption, explored James D. Chambers, PhD, MPharm, MSc, associate professor at the Tufts Medical Center Institute for Clinical Research and Health Policy Studies, in an interview.
A Banner Year for Biosimilars: The 19 FDA Approvals From 2024
January 21st 2025In 2024, the FDA approved 19 biosimilars across various therapeutic areas, including the first biosimilars for ustekinumab and denosumab, marking significant progress in expanding treatment options and market competition.
FTC Releases Second Report on PBMs Meddling in Generic Drug Markets
January 19th 2025The 3 largest pharmacy benefit managers (PBMs) increased many specialty generic drugs prices by hundreds of percent, with some drugs seeing thousands of percent markups, according to the Federal Trade Commission (FTC)’s second interim report on PBM practices.